Rosen Law Firm Announces Investigation of Shengtai Pharmaceutical In Connection With Going Private Proposal from its Chairman and CEO – SGTI

NEW YORK--(BUSINESS WIRE)--The Rosen Law Firm is investigating the Board of Directors of Shengtai Pharmaceutical Inc. (OTC: SGTI) for possible breaches of fiduciary duty and other violations of state law in connection with a going private proposal from its Chairman and Chief Executive Officer.

If you would like to join the action please email or call Phillip Kim or Kevin Chan, toll-free, at 866-767-3653; or email at [e-mail] or [e-mail]. There is no cost or obligation to you.

Under the terms of the proposal, offered by SGTI’s Chairman and CEO, Mr. Qingtai Liu, shareholders will receive $1.65 for each share of Shengtai Pharmaceutical stock they own. The investigation relates to whether the proposal for $1.65/share is fair to public shareholders and whether Shengtai Pharmaceutical’s Board breached its fiduciary duties in connection with the offer.

If you own Shengtai Pharmaceutical common stock and wish to obtain additional information, you may contact Phillip Kim or Kevin Chan of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at [e-mail] or [e-mail].

The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.